Methods: This open-label, randomized, controlled study involved 60 patients with CTS at the Azerbaijan Medical University (Baku, Azerbaijan) and Research Institute of Medical Rehabilitation between 20 years. The objective of the study was to evaluate the effectiveness of a novel product containing uridine and cytidine monophosphate (Nucleo CMP Forte™) in combination with ES for the treatment of CTS. To date, none of the studies have determined the optimal combination of pyrimidine nucleotides and electrical stimulation (ES) in CTS patients. Store at a temperature not exceeding 30C.Introduction: Carpal Tunnel Syndrome (CTS) is the most common and best well-known cause of peripheral nerve compression. The feasibility of taking is determined depending on the prevalence of the benefits of taking over the potential risk.įeatures of the effect of the drug on the ability to drive vehicles or other potentially dangerous mechanismsĭue to the low toxicity of the drug, the likelihood of an overdose is small. – children and adolescents up to 18 years of age – hypersensitivity to the components of the drug Have not been described, but in case of any adverse reactions associated with the use of the drug, consult your doctor. The course of treatment, if necessary, up to 6 months. Nucleo C.M.P Forte is administered orally:Īdults: 1-2 capsules 3 times a day from 1 month to 3 months. – neuralgia of the facial, trigeminal, intercostal nerves As a result, inflammation decreases and the sensitivity of the damaged axon site normalizes, which contributes to the restoration of axonal transport. Thus, a stable trophic effect, more complete maturation and regeneration of axonal nerve fibers is ensured. forte provides the body with the phosphate groups needed to combine monosaccharides with ceramines to form nerve sheaths, and phosphatidic acids that make up sphingomyelin and glycerophospholipids, the main components of the myelin sheath. Thus, the combination of the action of CMP and UTP contributes to the regeneration of the myelin sheath, the correct conduction of nervous excitation and the restoration of muscle trophism. This leads to intense metabolic activity, which in turn promotes the process of regeneration of the myelin sheath, regulating demyelination in peripheral nerve injuries. In general, CMP and UTP are involved in the synthesis of phospholipids and glycolipids, which mainly make up the myelin sheath and other neural structures. In addition, it acts as an energy source during muscle contraction.

UTP acts as a coenzyme in the synthesis of glycolipids, neuronal structures and myelin sheath, complementing the action of CMP. CMP is also a precursor of nucleic acids (DNA and RNA), which, in turn, are the main elements of cellular metabolism (for example, in protein synthesis). Nucleo CMP Forte contains a number of nucleotides: cytidine monophosphate (CMP), uridine triphosphate (UTP), which are widely used to treat diseases of the PNS (peripheral nervous system).įrom a biochemical point of view, the action of these two components can be described as follows: CMP takes part in the synthesis of a complex of lipids that form the neuronal membrane, mainly sphingomyelin, the main component of the myelin sheath. However, radioactive traces were found even 72 hours after administration, confirming its contribution to the body’s metabolic processes. CMP is eliminated in the first phase as cytosine and then as uridine. With regard to the beta phase of distribution (elimination), the half-life is about 8 hours. The half-life is 1.5 to 5 hours in the alpha distribution phase.

ethically and legally.Įxperimental animal assays have shown that peak plasma concentrations for both CMP and UTP are reached 20 minutes after oral administration. It is for this reason that it is difficult to perform a typical pharmacokinetic analysis with drug administration and content analysis corresponding to external administration in biological fluids using conventional analytical methods, since this would require the introduction of a radioactively labeled product to allow differentiation of organic contents from external administration, and such an action is questioned. These nucleotides are present in the body.

The drug Nucleo CMF Forte is an association of two nucleotides: CMP and UTP. There are no data on its pharmacokinetic properties in humans.

Pharmacological properties Pharmacokinetics Capsule composition: black iron oxide E172, titanium dioxide E171, gelatin, indigo carmine E132.Excipients: citric acid, sodium citrate dihydrate, magnesium stearate, colloidal silicon dioxide, mannitol.Active ingredients: cytidine 5′-disodium monophosphate 5.00, uridine 5′- trisodium triphosphate, uridine 5′- disodium diphosphate, uridine 5′- disodium monophosphate (total) 3.00 (equivalent to uridine content) (1.33).

Nucleo cmp forte ingredients